SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:prod.swepub.kib.ki.se:144469021"
 

Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:144469021" > Targeting Plk1 with...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00002703naa a2200337 4500
001oai:prod.swepub.kib.ki.se:144469021
003SwePub
008240811s2020 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1444690212 URI
024a https://doi.org/10.1038/s41598-020-59653-52 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Goroshchuk, Ou Karolinska Institutet4 aut
2451 0a Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients
264 c 2020-02-14
264 1b Springer Science and Business Media LLC,c 2020
520 a B-cell acute lymphoblastic leukemia (B-ALL) accounts for nearly one fifth of all childhood cancers and current challenges in B-ALL treatment include resistance, relapse and late-onset side effects due to the chemotherapy. To overcome these hurdles, novel therapies need to be investigated. One promising target is Polo-like kinase 1 (Plk1), a key regulator of the cell cycle. In this study, the Plk family expression is investigated in primary peripheral blood and bone marrow mononuclear cells from ten pediatric B-ALL patients. For the first time, short interfering RiboNucleic Neutrals (siRNNs) that enter cells without a transfection reagent are used to target Plk1 mRNA in primary cells from pediatric B-ALL patients. Our results show that the expression of Plk1 and Plk4 is significantly higher in pediatric B-ALL patients compared to healthy donors. Moreover, treatment of primary peripheral blood and bone marrow mononuclear cells from pediatric B-ALL patients, cultured ex vivo, with Plk1-targeting siRNNs results in cleavage of Plk1 mRNA. Importantly, the Plk1 knockdown is specific and does not affect other Plk members in contrast to many small molecule Plk1 inhibitors. Thus, Plk1 is a potential therapeutic target in pediatric B-ALL and selective targeting of Plk1 can be achieved by the use of siRNNs.
700a Vidarsdottir, L4 aut
700a Bjorklund, ACu Karolinska Institutet4 aut
700a Hamil, AS4 aut
700a Kolosenko, Iu Karolinska Institutet4 aut
700a Dowdy, SF4 aut
700a Palm-Apergi, Cu Karolinska Institutet4 aut
710a Karolinska Institutet4 org
773t Scientific reportsd : Springer Science and Business Media LLCg 10:1, s. 2688-q 10:1<2688-x 2045-2322
856u https://www.nature.com/articles/s41598-020-59653-5.pdf
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:144469021
8564 8u https://doi.org/10.1038/s41598-020-59653-5

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy